Arai Y, Kido C, Ota K, Endo T, Suyama K
Gan To Kagaku Ryoho. 1985 Feb;12(2):278-83.
Sixty patients with advanced cancers were treated with intraarterial infusion chemotherapy using a subcutaneously implanted silicone reservoir. Forty-five patients received a low dose-intermittent intraarterial infusion chemotherapy employing either combination MFC (MMC 4 mg, 5-FU 500 mg, Ara-C 40 mg) at intervals of two weeks or MMC 4 mg weekly. The results were as follows. (1) Among 30 cases, where objective evaluation of the initial response was possible, partial responses (PR) were observed in 15 cases (50%). (2) No severe complication was observed using this protocol. Only one case out of the 45 needed to discontinue the medication because of bone marrow suppression. (3) Among 28 cases, where follow-up data were available, the average hospital-free interval was 207 days. The average ratio of hospital-free interval to survival period was 56.4%. The results indicate that our method is beneficial as a maintenance chemotherapy for patients with advanced cancers, because it is effective, safer and improves the quality of life.
60例晚期癌症患者采用皮下植入硅胶储液器进行动脉内灌注化疗。45例患者接受低剂量间歇动脉内灌注化疗，每两周采用MFC联合方案（丝裂霉素4mg、氟尿嘧啶500mg、阿糖胞苷40mg）或每周使用丝裂霉素4mg。结果如下：（1）在30例可对初始反应进行客观评估的病例中，15例（50%）出现部分缓解（PR）。（2）采用该方案未观察到严重并发症。45例中只有1例因骨髓抑制需要停药。（3）在有随访数据的28例病例中，平均无住院间隔时间为207天。无住院间隔时间与生存期的平均比例为56.4%。结果表明，我们的方法作为晚期癌症患者的维持化疗是有益的，因为它有效、更安全且提高了生活质量。
